Bachem to host webinar on CEPS Peptiligase selection

Bubendorf, Switzerland: –The latest webinar to be hosted by leading peptides and oligonucleotides partner Bachem AG will explore the possibilities of selecting and engineering peptiligases to achieve highest efficacy in the synthesis of specific linear and cyclic peptide drugs and drug conjugates.

The one hour free-to-register webinar ‘CEPS Technology – Peptiligase Selection & Engineering’ will be held on Tuesday, May 25, commencing at 1730hrs CEST (UTC+2).

Chemo Enzymatic Peptide Synthesis Technology

The webinar will feature a principal speaker from EnzyTag, who developed the innovative peptiligase-based Chemo Enzymatic Peptide Synthesis (CEPS) technology that offers substantial advantages for efficiency and sustainable greener manufacturing.

The session will explore how selection and engineering of the peptiligase enzyme within CEPS can be used to optimize new and more economic manufacturing processes for linear peptide drugs and small proteins. It will also show how potential of the peptiligase technology can also extend to areas such as macrocyles (cyclotides), antibody-drug conjugates (ADCs) and conjugated dual inhibitors.

EnzyTag CEPS processes for complex peptide API’s

As a company committed to excellence in the fields of solid phase, hybrid, and solution phase peptide chemistry of therapeutic peptides, Bachem is pleased to offer EnzyTag a further platform to discuss its innovative technology, following an earlier webinar that presented the basic CEPS platform.

Principal speaker EnzyTag’s co-founder Dr. Leendert van den Bos, who studied bio-organic chemistry at Leiden University and has worked with Organon BioSciences, Schering-Plough, Merck Sharp & Dohme and Aspen Pharmacare before helping to set up EnzyTag in 2018 to focus on development of chemo-enzymatic processes for complex peptide API’s.

Moderator for the webinar will be Bachem Bubendorf Business Development Manager Seamus White, who is located in Northern Ireland and is the primary contact for Bachem partners in the UK and Ireland in the areas of GMP peptide API manufacture and development, supports customers through all project phases from preclinical research and IND enabling toxicology studies to process validation and commercialization.

The Webinar will be hosted on the Zoom platform with registration available online (see Resources).

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.  With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.  Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

Under its banner Leading Partner in Tides, Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.

Bachem has five production sites in the US, UK and Switzerland along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, and new chemical entities (NCEs) at preclinical, clinical and production scales.

Further information at: www.bachem.com

Resources

Click on Bachem webinar ‘CEPS Technology – Peptiligase Selection & Engineering’ to register for the event.
Click on Bachems News to see latest News & Events.